Please ensure Javascript is enabled for purposes of website accessibility

Abbott Laboratories Beats Revenue Expectations With Balanced Growth

By Jim Crumly - Updated Jan 22, 2020 at 1:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Dividend Aristocrat also gave strong guidance for 2020.

Abbott Laboratories (ABT 1.77%) released its fourth-quarter  report Wednesday morning, beating expectations for revenue and meeting its guidance for earnings per share. Shares were up by about 3% on the news.

For the quarter, revenue rose by 7.1% year over year to $8.31 billion  compared to analysts' consensus estimate of $8.26 billion, and was up 8.5% after excluding foreign currency effects and a discontinued business. Adjusted earnings per share were up 17.3% to $0.95, precisely hitting the midpoint of the guidance range management provided three months ago.

Abbott's largest segment, medical devices, provided its strongest sales gain -- 11.3%, excluding foreign currency impacts. Sales of the company's continuous glucose monitoring system, FreeStyle Libre, increased 62%, and sales of the MitraClip heart valve implant product grew 29%.

Stethoscope and an upward graph.

Image source: Getty Images.

Abbott's other three segments delivered solid growth as well, led by its branded generic drug business targeted at emerging markets, which had organic growth of 10%. The diagnostics unit's sales grew by 6.4%, and the nutrition segment had organic sales growth of 5.8%.

Management's newly released guidance for 2020 forecasts sales growth of between 7% and 8%, excluding currency impacts, which is above the 6.4% growth that analysts have been modeling. The company expects adjusted EPS for the year to fall in the $3.55 to $3.65 range, which would be growth of 11% at the midpoint. That's consistent with analysts' consensus estimate.

Abbott's well-managed, diversified healthcare business is a model of consistency, hitting its guidance quarter after quarter, and the market is applauding that quality today, to the benefit of shareholders in this Dividend Aristocrat.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
$109.88 (1.77%) $1.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.